HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.

Abstract
Reocclusion of coronary arteries is a major problem after successful thrombolysis in patients with acute myocardial infarction. We evaluated in a canine model of coronary thrombosis which is known to elicit reocclusion, whether an increased single i.v. bolus dose or two boli of the novel t-PA variant BM 06.022 improved coronary blood flow after reperfusion compared to i.v. injection of a standard single dose of BM 06.022. Double bolus administration, but not an increased single bolus dose of BM 06.022 significantly increased the maximum achieved coronary blood flow, prolonged the cumulative patency time, maintained blood flow at the end of the experiments, and reduced residual thrombus wet weight. Thus, double bolus administration improves coronary blood flow after reperfusion in the dog.
AuthorsU Martin, G Sponer, R König, A Smolarz, W Meyer-Sabellek, K Strein
JournalBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 3 Issue 2 Pg. 139-47 (Apr 1992) ISSN: 0957-5235 [Print] England
PMID1606285 (Publication Type: Journal Article)
Chemical References
  • Fibrinolytic Agents
  • Recombinant Proteins
  • reteplase
  • Tissue Plasminogen Activator
Topics
  • Animals
  • Coronary Circulation (drug effects)
  • Coronary Thrombosis (drug therapy, physiopathology)
  • Disease Models, Animal
  • Dogs
  • Female
  • Fibrinolytic Agents (administration & dosage)
  • Injections, Intravenous
  • Male
  • Myocardial Reperfusion
  • Recombinant Proteins (administration & dosage)
  • Thrombolytic Therapy (methods)
  • Tissue Plasminogen Activator (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: